» Articles » PMID: 30684209

Tollgate-based Progression Pathways of ALS Patients

Overview
Journal J Neurol
Specialty Neurology
Date 2019 Jan 27
PMID 30684209
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To capture ALS progression in arm, leg, speech, swallowing, and breathing segments using a disease-specific staging system, namely tollgate-based ALS staging system (TASS), where tollgates refer to a set of critical clinical events including having slight weakness in arms, needing a wheelchair, needing a feeding tube, etc. METHODS: We compiled a longitudinal dataset from medical records including free-text clinical notes of 514 ALS patients from Mayo Clinic, Rochester-MN. We derived tollgate-based progression pathways of patients up to a 1-year period starting from the first clinic visit. We conducted Kaplan-Meier analyses to estimate the probability of passing each tollgate over time for each functional segment.

Results: At their first clinic visit, 93%, 77%, and 60% of patients displayed some level of limb, bulbar, and breathing weakness, respectively. The proportion of patients at milder tollgate levels (tollgate level < 2) was smaller for arm and leg segments (38% and 46%, respectively) compared to others (> 65%). Patients showed non-uniform TASS pathways, i.e., the likelihood of passing a tollgate differed based on the affected segments at the initial visit. For instance, stratified by impaired segments at the initial visit, patients with limb and breathing impairment were more likely (62%) to use bi-level positive airway pressure device in a year compared to those with bulbar and breathing impairment (26%).

Conclusion: Using TASS, clinicians can inform ALS patients about their individualized likelihood of having critical disabilities and assistive-device needs (e.g., being dependent on wheelchair/ventilation, needing walker/wheelchair or communication devices), and help them better prepare for future.

Citing Articles

Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis.

Berry J, Hagan M, Zhang J, Liu Y, Ciepielewska M J Comp Eff Res. 2025; 14(2):e240007.

PMID: 39836043 PMC: 11773918. DOI: 10.57264/cer-2024-0007.


Prognostic factors affecting ALS progression through disease tollgates.

Wu H, Erenay F, Ozaltin O, Dalgic O, Sir M, He Q J Neurol. 2024; 272(1):69.

PMID: 39680215 DOI: 10.1007/s00415-024-12819-x.

References
1.
Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

2.
Orrell R, Habgood J, Malaspina A, Mitchell J, Greenwood J, Lane R . Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci. 1999; 169(1-2):56-60. DOI: 10.1016/s0022-510x(99)00216-6. View

3.
Mitsumoto H, Del Bene M . Improving the quality of life for people with ALS: the challenge ahead. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):329-36. DOI: 10.1080/146608200300079464. View

4.
Cedarbaum J, Stambler N . Disease status and use of ventilatory support by ALS patients. BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(1):19-22. DOI: 10.1080/146608201300079373. View

5.
Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka K . Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002; 25(5):709-714. DOI: 10.1002/mus.10090. View